Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 1/2.

Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 170 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Saracatinib (AZD0530) Chemical Structure

Saracatinib (AZD0530) Chemical Structure
Molecular Weight: 542.03

Validation & Quality Control

Customer Reviews(8)

Quality Control & MSDS

Related Compound Libraries

Src inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Inhibitor

    Bosutinib (SKI-606) Approved by FDA for Ph+ chronic myelogenous leukemia (CML).

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Inhibition Profile
  • Compare Src Inhibitors
    Compare Src Inhibitors
  • Research Area
  • Saracatinib (AZD0530) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 1/2.
Targets c-Src v-Abl
IC50 2.7 nM 30 nM [1]
In vitro Saracatinib also potently inhibits other Src tyrosine kinase family members including c-Yes, Fyn, Lyn, Blk, Fgr, and Lck with IC50 from 4-10 nM. Saracatinib sensitively inhibits Src Y530F NIH 3T3 with IC50 of 80 nM. Saracatinib significantly impairs the invasion of HT1080 cells through a 3-dimensional collagen matrix and completely inhibits EGF-induced cell scattering in NBT-II bladder cancer cells. [1] Saracatinib potent inhibits Src activation in DU145 and PC3 cells, which through inhibition of Y419 phosphorylation. Saracatinib inhibits the growth of prostate cancer including PC3, DU145, CWR22Rv1 and LNCaP, while Saracatinib shows low activity in LAPC-4, PZ-HPV7 and RWPE-1 cells. Saracatinib induces cell cycle arrest at G1/S but not caspase 3 cleavages. Saracatinib also significantly inhibits DU145 and PC3 migration in the Boyden chamber. [2] Saracatinib gives a potent and sustained blockage of AKT and enhances the sensitivity to irradiation in A549 and Calu-6 cells. [3] Saracatinib inhibits osteoclast in activity, resorption and formation. Saracatinib also reversibly prevents osteoclast precursor migration. [4]
In vivo Saracatinib shows great tumor growth inhibition in Src3T3 allografts and a moderate growth delay in Calu-6, MDA-MB-231, AsPc-1 and BT474C xenografts. [1] Saracatinib shows great antitumor activity in orthotopic DU145 xenograft mice at a dose of 25mg/kg (orally administered, daily). [2]
Features The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Protocol(Only for Reference)

Kinase Assay: [1]

Kinase Assay IC50 of tyrosine kinase activity is measured by an enzyme-linked immunosorbent assay (ELISA) with recombinant catalytic domains of a panel of receptor and non-receptor tyrosine kinases (in some cases only part of the catalytic domain is used). Saracatinib dose ranges from 0.001-10 mM. Specificity assays against a panel of serine/threonine kinases are performed using a filter capture assay with 32P. Briefly, multidrop 384 plates containing 0.5 μL Saracatinib or controls (DMSO) alone or pH 3.0 buffer controls) are incubated with 15 μL of enzyme plus peptide/protein substrate for 5 min before the reaction is initiated by the addition of 10 μL of 20 mM Mg-ATP. For all enzymes the final concentration is approximated to the Michaelis constant (Km). Assays are carried out for 30min at room temperature before termination by the addition of 5 μL orthophosphoric acid. After mixing, the well contents are harvested onto a P81 Unifilter plate, using orthophosphoric acid as the wash buffer. Then IC50 is calculated.

Cell Assay: [1]

Cell lines PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 and RWPE-1 cells
Concentrations 62.5 nM - 16 mM
Incubation Time 1, 3 and 5 days
Method Cells are seeded at a density of 2× 103 in 96-well plates and incubated overnight. Then Saracatinib (62.5 nM-16 mM) is added to the cells. After 1, 3 and 5 days, culture medium is removed followed by addition of 0.2 mL DMSO per well and continuous shaking of plates at 200 rotations per minute for 15min. Then IC50 is measured by MTT metho

Animal Study: [1]

Animal Models CB17 mice are implanted with DU145 cells.
Dosages 25 mg/kg
Administration Orally administered daily
Solubility 0.5% methylcellulose/0.2% Tween 80, 30 mg/mL
1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00752206 Recruiting Osteosarcoma Sarcoma Alliance for Research through Collaboration|AstraZeneca 2009-03 Phase 2
NCT00853983 Completed Healthy AstraZeneca 2009-03 Phase 1
NCT01000896 Withdrawn Cancer|Non Small Cell Lung Cancer|Epithelial Ovarian Cancer AstraZeneca 2010-01 Phase 1
NCT01267266 Active, not recruiting Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) 2010-12 Phase 2
NCT01864655 Not yet recruiting Alzheimer's Disease Yale University|Stephen M. Strittmatter 2013-07 Phase 1

Chemical Information

Download Saracatinib (AZD0530) SDF
Molecular Weight (MW) 542.03
Formula

C27H32ClN5O5

CAS No. 379231-04-6
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (184 mM)
Water <1 mg/mL (<1 mM)
Ethanol 100 mg/mL (184 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(5-chlorobenzo[d][1,3]dioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.54203 5.4203 10.8406 16.2609

Research Area

Customer Reviews (8)


Click to enlarge
Rating
Source Cancer Res, 2011, 71(24), 7547-57. Saracatinib (AZD0530) purchased from Selleck
Method Tumor xenograft experiments
Cell Lines tumor xenografted nude mice
Concentrations 25 mg/kg
Incubation Time 4 weeks
Results tumor xenograft experiments in nude mice showed that orally saracatinib administration could also alleviate instigative tumor formation induced by stable LHBs expression in Huh7 and SK-Hep1 cells .

Click to enlarge
Rating
Source J Biomol Screen, 2013, 18(1), 54-66. Saracatinib (AZD0530) purchased from Selleck
Method 3D Tumor Growth Assay
Cell Lines PC-3M cells
Concentrations 0-10 uM
Incubation Time 7 d
Results Reduction of colony size was observed for a number of established anticancer drugs, and IC 50 values for those reference compounds were determined based on the average area size of the cluster. IC 50 values were determined in two independent experiments and were quite reproducible.

Click to enlarge
Rating
Source J Biomol Screen, 2013, 18(1), 54-66. Saracatinib (AZD0530) purchased from Selleck
Method 3D Tumor Growth Assay
Cell Lines PC-3M cells
Concentrations 0-10uM
Incubation Time 7 day
Results Reduction of colony size was observed for a number of established anticancer drugs, and IC 50 values for those reference compounds were determined based on the average area size of the cluster. IC 50 values were determined in two independent experiments and were quite reproducible.

Click to enlarge
Rating
Source Translational Oncology, 2011, 4, 92-100. Saracatinib (AZD0530) purchased from Selleck
Method Western Blot
Cell Lines Hs683 cells
Concentrations 10 μM
Incubation Time 4 d
Results Figure 4 shows that AZD0530 prevented TMZ-induced soluble caveolin-1 expression but did not change basal levels of soluble caveolin-1 in Hs683 GBM cells. In contrast, erlotinib increased soluble caveolin-1 expression to a similar degree as TMZ in these Hs683 GBM cells.

Click to enlarge
Rating
Source Mol Cancer Res, 2011, 9, 249-258. Saracatinib (AZD0530) purchased from Selleck
Method Cell Viability Assay
Cell Lines MDA-MB-231/1205Lu cells
Concentrations 50 uM
Incubation Time 1 h
Results To verify this observation, we used a second Src inhibitor, AZD0530, which also caused cell rounding (data not shown) and TRAIL sensitization.

Click to enlarge
Rating
Source Cancer Biol Ther, 2011, 12(3), 215-28. Saracatinib (AZD0530) purchased from Selleck
Method Cell viability assays
Cell Lines embryonic fibroblasts
Concentrations 125 nM
Incubation Time 48 h
Results In transformed embryonic fibroblasts genetically deleted for toxic BH3 domain proteins BAX and BAK, but not deleted for BID, the combination of a SRC inhibitor (AZD0530; PP2; dasatinib) with a CHK1 inhibitor (UCN-01, AZD7762) was unable to cause cell killing.

Click to enlarge
Rating
Source Cancer Res, 2011, 71(24), 7547-57. Saracatinib (AZD0530) purchased from Selleck
Method Cell proliferation assay
Cell Lines Huh7 cells/SK-Hep1 cells
Concentrations 1 μmol/L
Incubation Time
Results Results of cell proliferation assay showed that saracatinib treatment could significantly atten-uate promotive hepatoma cellular proliferation conferred by stable LHBs expression in Huh7 and SK-Hep1 cells (Fig. A and B).

Click to enlarge
Rating
Source Dr Shuxin Han of Kent State University. Saracatinib (AZD0530) purchased from Selleck
Method IP assay, Q-PCR assay
Cell Lines Primary human hepatocytes
Concentrations 5 μM
Incubation Time 6 h
Results

Product Citations (14)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Inhibitors

  • PP2

    PP2 is Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PRT062607 (P505-15, BIIB057) HCl

    PRT062607 (P505-15) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 1/2.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.

  • KX2-391

    KX2-391 (KX01), the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 1/2.

  • Ibrutinib (PCI-32765)

    Ibrutinib is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

  • Imatinib Mesylate (STI571)

    Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.

  • Ponatinib (AP24534)

    Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.

Recently Viewed Items

Tags: buy Saracatinib (AZD0530) | Saracatinib (AZD0530) supplier | purchase Saracatinib (AZD0530) | Saracatinib (AZD0530) cost | Saracatinib (AZD0530) manufacturer | order Saracatinib (AZD0530) | Saracatinib (AZD0530) distributor
Contact Us